Sequoia Financial Advisors LLC Buys Shares of 5,811 Ascendis Pharma A/S (NASDAQ:ASND)

Sequoia Financial Advisors LLC purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 5,811 shares of the biotechnology company’s stock, valued at approximately $732,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Goldman Sachs Group Inc. boosted its holdings in Ascendis Pharma A/S by 3,024.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,754,458 shares of the biotechnology company’s stock worth $205,903,000 after acquiring an additional 1,698,302 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Ascendis Pharma A/S by 39.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,828,267 shares of the biotechnology company’s stock worth $345,417,000 after purchasing an additional 796,087 shares in the last quarter. Wellington Management Group LLP grew its position in Ascendis Pharma A/S by 14.6% during the 1st quarter. Wellington Management Group LLP now owns 4,665,579 shares of the biotechnology company’s stock valued at $547,552,000 after purchasing an additional 594,855 shares during the last quarter. Capital International Investors bought a new stake in Ascendis Pharma A/S during the 1st quarter valued at about $28,894,000. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Ascendis Pharma A/S by 16.3% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,264,470 shares of the biotechnology company’s stock valued at $118,405,000 after acquiring an additional 176,948 shares in the last quarter.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock opened at $145.23 on Tuesday. Ascendis Pharma A/S has a 1-year low of $66.03 and a 1-year high of $161.00. The company’s fifty day simple moving average is $149.10 and its 200-day simple moving average is $123.28. The stock has a market capitalization of $8.46 billion, a PE ratio of -15.70 and a beta of 0.50.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, topping analysts’ consensus estimates of ($2.15) by $0.49. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. The company had revenue of $148.62 million for the quarter, compared to analysts’ expectations of $97.02 million. As a group, research analysts anticipate that Ascendis Pharma A/S will post -4.18 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on ASND. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Monday, December 25th. JPMorgan Chase & Co. raised their price target on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a report on Tuesday, April 2nd. Wells Fargo & Company lifted their price target on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. Citigroup raised their target price on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a “buy” rating in a report on Thursday, February 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $173.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, April 1st. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.25.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.